NasdaqCM - Nasdaq Real Time Price • USD
Viking Therapeutics, Inc. (VKTX)
At close: April 25 at 4:00 PM EDT
Pre-Market: 5:12 AM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 10 | 10 | 11 | 10 |
Avg. Estimate | -0.28 | -0.29 | -1.13 | -1.53 |
Low Estimate | -0.36 | -0.4 | -1.53 | -2.26 |
High Estimate | -0.19 | -0.2 | -0.82 | -1.16 |
Year Ago EPS | -0.19 | -0.23 | -0.91 | -1.13 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 10 | 10 | 11 | 10 |
Avg. Estimate | -- | -- | -- | -- |
Low Estimate | -- | -- | -- | -- |
High Estimate | -- | -- | -- | -- |
Year Ago Sales | -- | -- | -- | -- |
Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
---|---|---|---|---|
EPS Est. | -0.19 | -0.22 | -0.25 | -0.28 |
EPS Actual | -0.19 | -0.23 | -0.25 | -0.26 |
Difference | 0 | -0.01 | 0 | 0.02 |
Surprise % | 0.00% | -4.50% | 0.00% | 7.10% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.28 | -0.29 | -1.13 | -1.53 |
7 Days Ago | -0.28 | -0.29 | -1.12 | -1.52 |
30 Days Ago | -0.28 | -0.29 | -1.12 | -1.51 |
60 Days Ago | -0.28 | -0.29 | -1.13 | -1.48 |
90 Days Ago | -0.28 | -0.29 | -1.12 | -1.47 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | 2 | 1 | 2 |
Growth Estimates
CURRENCY IN USD | VKTX | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -47.40% | -- | -- | 2.60% |
Next Qtr. | -26.10% | -- | -- | 13.40% |
Current Year | -24.20% | -- | -- | 5.20% |
Next Year | -35.40% | -- | -- | 13.30% |
Next 5 Years (per annum) | 40.00% | -- | -- | 11.11% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 4/25/2024 |
Maintains | Oppenheimer: Outperform to Outperform | 3/27/2024 |
Maintains | Oppenheimer: Outperform to Outperform | 3/26/2024 |
Maintains | BTIG: Buy to Buy | 3/26/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 3/26/2024 |
Reiterates | Stifel: Buy to Buy | 3/15/2024 |
Related Tickers
MDGL Madrigal Pharmaceuticals, Inc.
194.38
-5.02%
NVO Novo Nordisk A/S
125.79
-0.29%
ALT Altimmune, Inc.
7.20
+1.69%
IOVA Iovance Biotherapeutics, Inc.
11.54
-1.45%
VRTX Vertex Pharmaceuticals Incorporated
397.70
-0.76%
RXRX Recursion Pharmaceuticals, Inc.
7.84
-1.26%
IBRX ImmunityBio, Inc.
5.11
+6.02%
DAWN Day One Biopharmaceuticals, Inc.
13.21
-13.03%
CRSP CRISPR Therapeutics AG
53.73
-3.45%
JANX Janux Therapeutics, Inc.
47.10
-2.30%